Piramal Pharma FY26 Revenue Down 3% YoY

Revenue fell 3% YoY to ₹8,869 Cr in FY26, with Q4 flat at ₹2,752 Cr versus ₹2,754 Cr.
EBITDA dropped 28% YoY to ₹1,135 Cr for FY26, with Q4 EBITDA down 16% to ₹507 Cr, margin fell to 18%.
Net profit after exceptional items was ₹154 Cr in FY26 (₹91 Cr FY25), after a ₹176 Cr impairment on intangible assets.
Capex of US$94 Mn was spent in FY26 on Lexington and Riverview expansions; net debt remained unchanged at ₹4,140 Cr.